Drug Trial Radar · NCT05753566
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Mar 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Mar 2023
Primary completion
Mar 2027
Study completion Mar 2028
Sponsor
- Lead sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Jiangsu HengRui Medicine Co., Ltd.
- First posted
- Mar 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy(ADT) and standard salvage radiation therapy(SRT) or rezvilutamide in combination with ADT in prostate cancer patients with biochemical recurrence of prostate-specific antigen(PSA) persistence after radical prostatectomy(RP).
Conditions
- Prostate Cancer
- Biochemical Recurrence
Interventions
RezvilutamideDrug
Specifications of 80 mg; orally, once a day
Androgen deprivation therapy (ADT)Drug
Androgen deprivation therapy (ADT), the ADT used by each subject will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescription information
SRTRadiation
SRT according to standard of care (66.6-72 grays will be delivered to the bed of prostate ,\~50.4 grays to the pelvis if needed)
Primary outcomes
What the sponsor says the trial is designed to measure.
- 2-year biochemical progression-free survivalTime frame: 24 months
- 3-year biochemical progression-free survivalTime frame: 36 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China · Recruiting
JiangSu Cancer Hospital
Nanjing, Jiangsu, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.